Jazz Pharmaceuticals opened higher at $209.63, compared with its previous close of $207.83. In the last trading session, the stock traded between $209.35 and $213.80. It showed an upward intraday trend.
An investment of $100 made 5 years ago in Jazz Pharmaceuticals is now worth
$ 160.63
giving a profit of
$ 60.63 (60.63%)
Note: Past profits do not guarantee future returns.
Rating from 18 Analysts
Today's Change
+$5.87 (+2.82%)
Day High
$213.80
Day Low
$209.35
Day Open
$209.63
Prev Close
$207.83
Volume
4,05,336
1W Return
-0.42%
1M Return
-8.07%
3M Return
-16.45%
6M Return
6.89%
1Y Return
57.44%
Market Cap ($ Mn)
13,872
PE Ratio
16.76
PB Ratio
3.30
PEG Ratio
0.22
ROE
-8.79%
ROCE
-4.45%
EPS (TTM)
$2.98
1 Week
-0.42%
1 Month
-8.07%
3 Months
-16.45%
6 Months
6.89%
9 Months
30.32%
Jazz Pharmaceuticals presents Ziihera survival data at ESMO 2026
Jazz Pharmaceuticals plc presented updated overall survival results from the Phase 3 HERIZON-GEA-01 trial at ESMO Congress 2026. The study evaluated Ziihera combined with chemotherapy, with or without Tevimbra, for first-line treatment of HER2-positive gastroesophageal adenocarcinoma. Data from the second interim and final formal analysis was shared as a late-breaking rapid oral presentation (LBA79).
7 days agoJazz Pharmaceuticals prices $1.1B exchangeable notes due 2032
Jazz Pharmaceuticals priced $1.1 billion in 1.875% exchangeable senior notes due 2032. Initial purchasers have an option to buy an additional $150.0 million in notes. Company announced concurrent share repurchases of $225.0 million at $249.29 per share. Notes are guaranteed by Jazz Pharmaceuticals on a senior unsecured basis.
2mo agoFDA approves two Ziihera regimens for HER2+ gastric cancer
FDA approves two Ziihera regimens for first-line HER2+ GEA treatment. Median overall survival reached 26.4 months in Phase 3 trial. Zymeworks receives $250 million milestone payment from Jazz. Jazz shares fell 0.8% to $258.14 on Wednesday. Needham and Truist raised Jazz price targets to $310 and $281.
2mo agoJazz Pharmaceuticals acquires Actio Biosciences for $820M upfront
Jazz Pharmaceuticals is acquiring Actio Biosciences for $820 million upfront plus up to $500 million in milestones to secure ABS-1230, a potential first-in-class treatment for KCNT1+ epilepsy. The deal, expected to close in Q4 2026, includes a spin-out entity for other rare neurological assets, strengthening Jazz's position in rare epilepsies alongside Epidiolex.
2mo agoJazz Pharmaceuticals Q2 Results: Sales Beat Estimate, EPS Misses
Jazz Pharmaceuticals delivered mixed Q2 results with sales of $1.208 billion beating estimates by 8.29%, driven by 15.49% YoY growth. However, adjusted EPS of $5.71 missed the $6.18 consensus. The quarter marks a major turnaround from a prior-year loss of $(8.25) per share.
2mo agoJazz Pharmaceuticals raises FY26 sales guidance to $4.600B-$4.750B
Jazz Pharmaceuticals raises FY26 sales guidance to $4.600B-$4.750B, beating the $4.517B estimate and lifting the midpoint above prior expectations.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $540.00 | +1.95% | $1,36,868.94M | 31.55 | |
| $61.07 | +2.12% | $1,31,639.87M | 14.39 | |
| $222.76 | +4.01% | $88,933.81M | - | |
| $818.77 | +0.68% | $82,808.76M | 19.64 | |
| $897.85 | +0.68% | $56,462.20M | 38.99 | |
| $371.56 | -0.48% | $40,792.43M | 65.60 | |
| $190.27 | +0.82% | $40,781.71M | - | |
| $56.49 | -1.40% | $35,253.15M | 26.24 | |
| $65.93 | +1.71% | $29,357.11M | 32.37 | |
| $37.52 | +1.10% | $27,101.56M | - | |
| $111.59 | +15.07% | $24,369.25M | - | |
| $116.80 | -0.06% | $23,675.13M | 15.85 |
An investment of $100 made 5 years ago in Jazz Pharmaceuticals is now worth
$ 160.63
giving a profit of
$ 60.63 (60.63%)
Note: Past profits do not guarantee future returns.
